Localized Intermediate Risk Prostate Lesions clinical trials at UC Health
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated patients, as described above.